Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803

Kimmie Ng*, Shuji Ogino, Jeffrey A. Meyerhardt, Jennifer A. Chan, Andrew T. Chan, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Al B Benson III, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook, Charles S. Fuchs

*Corresponding author for this work

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

Original languageEnglish (US)
Pages (from-to)1540-1551
Number of pages12
JournalJournal of the National Cancer Institute
Volume103
Issue number20
DOIs
StatePublished - Oct 19 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Colonic Neoplasms
Recurrence
Survival
Disease-Free Survival
Adjuvant Chemotherapy
Confidence Intervals
Mutation
Neoplasms
Confounding Factors (Epidemiology)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ng, K., Ogino, S., Meyerhardt, J. A., Chan, J. A., Chan, A. T., Niedzwiecki, D., ... Fuchs, C. S. (2011). Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803. Journal of the National Cancer Institute, 103(20), 1540-1551. https://doi.org/10.1093/jnci/djr307
Ng, Kimmie ; Ogino, Shuji ; Meyerhardt, Jeffrey A. ; Chan, Jennifer A. ; Chan, Andrew T. ; Niedzwiecki, Donna ; Hollis, Donna ; Saltz, Leonard B. ; Mayer, Robert J. ; Benson III, Al B ; Schaefer, Paul L. ; Whittom, Renaud ; Hantel, Alexander ; Goldberg, Richard M. ; Bertagnolli, Monica M. ; Venook, Alan P. ; Fuchs, Charles S. / Relationship between statin use and colon cancer recurrence and survival : Results from CALGB 89803. In: Journal of the National Cancer Institute. 2011 ; Vol. 103, No. 20. pp. 1540-1551.
@article{6d645601a5314b95bdf93e81be2f9d00,
title = "Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803",
abstract = "Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9{\%}) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95{\%} confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95{\%} CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95{\%} CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.",
author = "Kimmie Ng and Shuji Ogino and Meyerhardt, {Jeffrey A.} and Chan, {Jennifer A.} and Chan, {Andrew T.} and Donna Niedzwiecki and Donna Hollis and Saltz, {Leonard B.} and Mayer, {Robert J.} and {Benson III}, {Al B} and Schaefer, {Paul L.} and Renaud Whittom and Alexander Hantel and Goldberg, {Richard M.} and Bertagnolli, {Monica M.} and Venook, {Alan P.} and Fuchs, {Charles S.}",
year = "2011",
month = "10",
day = "19",
doi = "10.1093/jnci/djr307",
language = "English (US)",
volume = "103",
pages = "1540--1551",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "20",

}

Ng, K, Ogino, S, Meyerhardt, JA, Chan, JA, Chan, AT, Niedzwiecki, D, Hollis, D, Saltz, LB, Mayer, RJ, Benson III, AB, Schaefer, PL, Whittom, R, Hantel, A, Goldberg, RM, Bertagnolli, MM, Venook, AP & Fuchs, CS 2011, 'Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803', Journal of the National Cancer Institute, vol. 103, no. 20, pp. 1540-1551. https://doi.org/10.1093/jnci/djr307

Relationship between statin use and colon cancer recurrence and survival : Results from CALGB 89803. / Ng, Kimmie; Ogino, Shuji; Meyerhardt, Jeffrey A.; Chan, Jennifer A.; Chan, Andrew T.; Niedzwiecki, Donna; Hollis, Donna; Saltz, Leonard B.; Mayer, Robert J.; Benson III, Al B; Schaefer, Paul L.; Whittom, Renaud; Hantel, Alexander; Goldberg, Richard M.; Bertagnolli, Monica M.; Venook, Alan P.; Fuchs, Charles S.

In: Journal of the National Cancer Institute, Vol. 103, No. 20, 19.10.2011, p. 1540-1551.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relationship between statin use and colon cancer recurrence and survival

T2 - Results from CALGB 89803

AU - Ng, Kimmie

AU - Ogino, Shuji

AU - Meyerhardt, Jeffrey A.

AU - Chan, Jennifer A.

AU - Chan, Andrew T.

AU - Niedzwiecki, Donna

AU - Hollis, Donna

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Benson III, Al B

AU - Schaefer, Paul L.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Goldberg, Richard M.

AU - Bertagnolli, Monica M.

AU - Venook, Alan P.

AU - Fuchs, Charles S.

PY - 2011/10/19

Y1 - 2011/10/19

N2 - Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

AB - Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

UR - http://www.scopus.com/inward/record.url?scp=80052956941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052956941&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr307

DO - 10.1093/jnci/djr307

M3 - Article

C2 - 21849660

AN - SCOPUS:80052956941

VL - 103

SP - 1540

EP - 1551

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 20

ER -